Outlive
LongevityResearchHub

Dynamic ecosystems of tumor drug resistance mechanisms: from molecular heterogeneity to systemic interventions.

TL;DR

Tumor drug resistance remains a significant challenge in the failure of cancer treatments, rooted in the complex dynamic adaptive evolution of tumors within the triad of "cell-microenvironment-host." Previous research methodologies have often concentrated on single-level mechanisms, such as gene mutations or alterations in specific signaling pathways, while neglecting the intricate interactions among tumors, their microenvironments, and the host. This paper proposes a novel theoretical framework

Credibility Assessment Preliminary — 46/100
Study Design
Rigor of the research methodology
5/20
Sample Size
Whether the study was sufficiently powered
7/20
Peer Review
Review status and journal reputation
18/20
Replication
Has this finding been independently reproduced?
6/20
Transparency
Funding disclosure and data availability
10/20
Overall
Sum of all five dimensions
46/100

Tumor drug resistance remains a significant challenge in the failure of cancer treatments, rooted in the complex dynamic adaptive evolution of tumors within the triad of "cell-microenvironment-host." Previous research methodologies have often concentrated on single-level mechanisms, such as gene mutations or alterations in specific signaling pathways, while neglecting the intricate interactions among tumors, their microenvironments, and the host. This paper proposes a novel theoretical framework-the "Dynamic Ecosystem of Tumor Resistance"-which integrates three levels: intrinsic tumor cell heterogeneity and plasticity, microenvironment interactions, and host systemic regulatory factors. The objective is to systematically explore key resistance mechanisms and their dynamic interactions across these levels, thereby elucidating the complex nature of resistance. This framework aims to stimulate further research into therapeutic strategies targeting tumor resistance and to provide novel insights for the development of clinical approaches to treating malignant tumors.

View Original Source

0 Comments